BASKING RIDGE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a
commercial-stage bioelectronic medicine company, today announced the company will be participating in the upcoming Evercore
ISI HealthCONx Conference in Boston, MA.
electroCore’s management is scheduled to present on Tuesday, November 27, 2018 at 2:20 PM Eastern Time. Interested parties
may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at:
www.electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its
platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and
rheumatology. The Company’s initial targets are the acute treatment of migraine and episodic cluster headache.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and
product development plans, its pipeline or potential markets for its technologies, and other statements that are not historical in
nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of
similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding
needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to commercialize gammaCore™, the willingness and degree of third-party payors
to provide adequate coverage and reimbursement for the use of gammaCore, competition in the industry in which electroCore operates,
overall market conditions, and continuing positive trends in prescriptions and user demand for our therapy. Any
forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the
forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking
statements, except as required by law. Investors should consult all of the information set forth herein and should also refer
to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at
www.sec.gov.
Contacts
Investors:
Greg Chodaczek or Lynn Lewis
Gilmartin Group
investors@electrocore.com
(646) 924-1769
or
Media:
Alexandra Canale
GCI Health
(617) 921-9353
alexandra.canale@gcihealth.com
